More European drugmakers to lower the cost of medicines in USA

22 December 2025

Three more European big pharmas have announced plans join US President Trump's scheme to have the majority of medicines to be produced in the USA with the aim of reducing drug prices for Americans.

Boehringer Ingelheim, German family-owned company, on Friday announced a broad agreement with the Trump Administration to lower the cost of medicines for American patients, in line with the conditions set out by the US President in his letter to the pharmaceutical industry dated July 31, 2025. This includes participating in a direct purchasing platform, TrumpRx.gov, that will allow American patients to purchase medicines from Boehringer at a significant discount.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK